Frontiers in Oncology | Cancer Immunity and Immunotherapy

Case Report

Accepted on 06 Aug 2026

Mature tertiary lymphoid structures in a metastatic urothelial carcinoma patient with an exceptional response to sequential immune checkpoint inhibitor and antibody-drug conjugate therapy

in Cancer Immunity and Immunotherapy

Kanta Hori
Takuto Ogasawara
Yuka Mizue
Hiroko Asanuma
Naoki Shijubou
Akihiro Yamashita
Ryo Kato
Jun Furumido
Takashige Abe
Keisuke Sato

Frontiers in Oncology

Opinion

Published on 06 Aug 2026

Intratumoral bacteria in cancer: from detection to biological relevance

in Cancer Immunity and Immunotherapy

Mingjie Ding
Hao Li
Wenzhi Guo

Frontiers in Oncology

doi 10.3389/fonc.2026.1904204

235 views

Original Research

Published on 06 Aug 2026

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types

in Cancer Immunity and Immunotherapy

Catia Gaspar
Benson Wu
Simone C. Stone
Valentin Sotov
Ben Wang
Collins Wangulu
Hal Berman
Aileigh Kay
Prabhjit Basra
Emily Van de Laar

Frontiers in Oncology

doi 10.3389/fonc.2026.1876853

330 views

Case Report

Published on 05 Aug 2026

Metachronous severe multisystem immune-related adverse events during tremelimumab plus durvalumab therapy for hepatocellular carcinoma: a clinicopathological autopsy case report

in Cancer Immunity and Immunotherapy

Takuto Nosaka
Junki Yamashita
Yu Akazawa
Tomoko Tanaka
Kazuto Takahashi
Tatsushi Naito
Masahiro Ohtani
Yukihiro Kimura
Yoshiaki Imamura
Hiroshi Tada

Frontiers in Oncology

doi 10.3389/fonc.2026.1830325

203 views

Original Research

Published on 04 Aug 2026

Coordinated dynamics of circulating neutrophils, regulatory T lymphocytes, myeloid derived suppressor cells and distinct granulocytic subsets reveal a complex immune network in metastatic colorectal cancer

in Cancer Immunity and Immunotherapy

Zafeiris Zafeiriou
Anna Koutoulaki
Despoina Aggouraki
Filippos Koinis
Nikolaos Vardakis
Alexandra Voutsina
Katerina Papadogiannaki
Konstantia Kotta
Eleni-Kyriaki Vetsika
Dimitris Mavroudis

Frontiers in Oncology

doi 10.3389/fonc.2026.1873352

354 views

Review

Accepted on 03 Aug 2026

Adenosine Signaling in Tumor Immune Escape: Metabolic Checkpoints, Myeloid Suppression, and Combination Immunotherapy

in Cancer Immunity and Immunotherapy

睿李
Shengbiao Li
Tongtong Zhang

Frontiers in Oncology

Systematic Review

Published on 03 Aug 2026

Immunotherapy plus targeted therapy for recurrent or metastatic head and neck squamous cell carcinoma: an updated meta-analysis and subgroup analysis by target mechanism

in Cancer Immunity and Immunotherapy

Wen Sun
Yanlin Wang
Hui Dong
Dianwei Liu

Frontiers in Oncology

doi 10.3389/fonc.2026.1892431

263 views

Systematic Review

Accepted on 31 Jul 2026

Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of Phase III Randomized Trials

in Cancer Immunity and Immunotherapy

Mariam Grazia Polito
luisana sisca
Davide Caruso
Antonella Cosimati
Carla Adriana Ramirez Reinaga
Etien Leka
Daniele Santini
Gian Paolo Spinelli

Frontiers in Oncology

348 views

Review

Accepted on 31 Jul 2026

Cryoablation Combined with Immunotherapy: New Strategies and Progress in the Treatment of Tumors

in Cancer Immunity and Immunotherapy

Yuxin Xiang
Lin Yu
Jia Li

Frontiers in Oncology

126 views

Original Research

Published on 31 Jul 2026

ctDNA-derived copy-number signatures associated with immune checkpoint inhibitor resistance beyond PD-L1 and TMB in advanced NSCLC

in Cancer Immunity and Immunotherapy

Pedro Gonzalez Santa-Catalina
Luis Posado-Domínguez
Álvaro López-Gutiérrez
Edel del Barco Morillo
Juan Carlos Redondo-González
Noelia Egido-Iglesias
Laura Corvo-Félix
Isabel Muela Bravo
Aline Rodrigues-Françoso
Lorena Bellido-Hernández

Frontiers in Oncology

doi 10.3389/fonc.2026.1876274

405 views

Review

Published on 31 Jul 2026

Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers

in Cancer Immunity and Immunotherapy

Chulan Yang
Xinan Long
Yangyang Ma
Lizhi Niu

Frontiers in Oncology

doi 10.3389/fonc.2026.1869239

340 views

Original Research

Accepted on 30 Jul 2026

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: A Single-Center Retrospective Study

in Cancer Immunity and Immunotherapy

Wenqiang Mo
Yinzhen Li
Luna Zhao
Yuan Liu
Qi Shu
Jing Fei

Frontiers in Oncology

122 views

Mini Review

Published on 29 Jul 2026

Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management

in Cancer Immunity and Immunotherapy

Orianne de la Brassinne Bonardeaux
Marie Moonen
Mai Linh Nguyen Trung
Helene Petitjean
Guy Jerusalem
Patrizio Lancellotti

Frontiers in Oncology

doi 10.3389/fonc.2026.1910598

328 views

Review

Published on 28 Jul 2026

Host systemic metabolism and cancer metabolic vulnerabilities: mechanisms and therapeutic opportunities

in Cancer Immunity and Immunotherapy

Rashid Mir
Jameel Barnawi
Naseh A Algehainy
Mohammed M. Jalal
Malik A. Altayar
Reema M Almotairi
Faris J Tayeb
Mamdoh S Moawadh
Ruqaiah I Bedaiwi
Kholoud S. Almasoudi

Frontiers in Oncology

doi 10.3389/fonc.2026.1897564

397 views

Review

Published on 24 Jul 2026

Biomarkers for predicting and monitoring the efficacy of cancer vaccines

in Cancer Immunity and Immunotherapy

Julia A. Remizova
Anastasia G. Volkova
Anna S. Makarova
Valentin V. Makarov
Vladimir S. Yudin
Anton A. Keskinov

Frontiers in Oncology

doi 10.3389/fonc.2026.1904586

448 views

Original Research

Accepted on 23 Jul 2026

Cutaneous Immune-Related Adverse Events Independently Predict Overall Survival with a Grade-Dependent Association in ICI-Treated Advanced NSCLC: A Time-Dependent Analysis

in Cancer Immunity and Immunotherapy

Tao Xu
Jia Li
Junqi Zhao
Daixi Wu
Zhening Liu
Yumin Zheng
Xinmeng Wang
Ye Zhai
Huijuan Cui

Frontiers in Oncology

156 views

Original Research

Published on 23 Jul 2026

Genetic landscape features associated with PD-L1 expression status in advanced lung adenocarcinoma: a targeted sequencing analysis

in Cancer Immunity and Immunotherapy

Mukun Huang
Zhongqiang Yao
Hua Zhang
Chuanjun Song
Mengzhu Wang
Jiangman Zhao
Shushen Ji
Keliang Zhu
Mengxin Zhao
Dan Zhang

Frontiers in Oncology

doi 10.3389/fonc.2026.1892351

378 views

Original Research

Published on 23 Jul 2026

Tumor-derived miR-126 promotes tumor progression through immune modulation beyond the local tumor environment

in Cancer Immunity and Immunotherapy

Takashi Akazawa
Yu Mizote
Tomoya Ekawa
Satomi Yoshida
Yachiyo Kumamoto
Yoichiro Harada
Hisataka Ogawa
Shunichi Watanabe
Shingo Hatoya
Norimitsu Inoue

Frontiers in Oncology

doi 10.3389/fonc.2026.1867336

309 views

Systematic Review

Published on 22 Jul 2026

Two decades of immunogenic cell death research: a bibliometric analysis of the 100 most cited publications

in Cancer Immunity and Immunotherapy

Li Guan
Lijuan Guo
Yuqiu Liu
Shengwei Bao
Mingyang Chen
Jia Luo
Huan Zhang
Sen Yang

Frontiers in Oncology

doi 10.3389/fonc.2026.1904609

370 views

Case Report

Published on 22 Jul 2026

Case Report: Refractory desmoplastic small round cell tumor: a report of a molecularly confirmed case with EWSR1–WT1 fusion

in Cancer Immunity and Immunotherapy

Na Li
Jianjun Jiang
Fang Tan
Qian Deng

Frontiers in Oncology

doi 10.3389/fonc.2026.1790371

552 views

Systematic Review

Published on 22 Jul 2026

Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis

in Cancer Immunity and Immunotherapy

Haripriya Parapparambil Surendran
Gopal Gopisetty
Senthil Jagannathan Rajappa
T. Subramanyeshwar Rao
M. K. Unnikrishnan

Frontiers in Oncology

doi 10.3389/fonc.2026.1859306

549 views

Hypothesis and Theory

Published on 20 Jul 2026

Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study

in Cancer Immunity and Immunotherapy

Paloma Sangro
Ana Landa-Magdalena
Miguel Sogbe
Teresa Zumarraga
Ignacio Matos
Mariano Ponz-Sarvise
Marina Crespo
María Esperanza Rodriguez-Ruiz
Anna Vilalta-Lacarra
Eduardo Castañón

Frontiers in Oncology

doi 10.3389/fonc.2026.1849425

612 views

Case Report

Published on 16 Jul 2026

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge

in Cancer Immunity and Immunotherapy

Jamila Raja
Shuo Li
Asal Patterson
Steve R. Martinez
Perry A. Soriano
Xiaowen Wang
Peter Y. Z. Jiang

Frontiers in Oncology

doi 10.3389/fonc.2026.1875467

784 views

Original Research

Published on 15 Jul 2026

E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice

in Cancer Immunity and Immunotherapy

Richard G. Hoover
Emily C. Matchett
Jacki Kornbluth

Frontiers in Oncology

doi 10.3389/fonc.2026.1874366

448 views

1,706 articles

articles

Mature tertiary lymphoid structures in a metastatic urothelial carcinoma patient with an exceptional response to sequential immune checkpoint inhibitor and antibody-drug conjugate therapy

Intratumoral bacteria in cancer: from detection to biological relevance

Immune profiling by bulk RNA-seq and multiplex immunofluorescence imaging across multiple cancer types

Metachronous severe multisystem immune-related adverse events during tremelimumab plus durvalumab therapy for hepatocellular carcinoma: a clinicopathological autopsy case report

Coordinated dynamics of circulating neutrophils, regulatory T lymphocytes, myeloid derived suppressor cells and distinct granulocytic subsets reveal a complex immune network in metastatic colorectal cancer

Adenosine Signaling in Tumor Immune Escape: Metabolic Checkpoints, Myeloid Suppression, and Combination Immunotherapy

Immunotherapy plus targeted therapy for recurrent or metastatic head and neck squamous cell carcinoma: an updated meta-analysis and subgroup analysis by target mechanism

Adjuvant immune checkpoint inhibitors across solid tumors: a meta-analysis of Phase III Randomized Trials

Cryoablation Combined with Immunotherapy: New Strategies and Progress in the Treatment of Tumors

ctDNA-derived copy-number signatures associated with immune checkpoint inhibitor resistance beyond PD-L1 and TMB in advanced NSCLC

Integrating cryoablation with immunotherapy in non-small cell lung cancer: mechanisms, clinical evidence, and translational barriers

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver gene-negative advanced non-squamous non-small cell lung cancer: A Single-Center Retrospective Study

Myotoxicity in the era of cancer immunotherapy: from mechanisms to multidisciplinary management

Host systemic metabolism and cancer metabolic vulnerabilities: mechanisms and therapeutic opportunities

Biomarkers for predicting and monitoring the efficacy of cancer vaccines

Cutaneous Immune-Related Adverse Events Independently Predict Overall Survival with a Grade-Dependent Association in ICI-Treated Advanced NSCLC: A Time-Dependent Analysis

Genetic landscape features associated with PD-L1 expression status in advanced lung adenocarcinoma: a targeted sequencing analysis

Tumor-derived miR-126 promotes tumor progression through immune modulation beyond the local tumor environment

Two decades of immunogenic cell death research: a bibliometric analysis of the 100 most cited publications

Case Report: Refractory desmoplastic small round cell tumor: a report of a molecularly confirmed case with EWSR1–WT1 fusion

Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis

Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study

Case Report: Durable remission in stage IV melanoma following strategic immune checkpoint inhibitor class rotation and rechallenge

E3 ubiquitin ligase NKLAM/RNF19b suppresses myc-driven B cell lymphomagenesis in Eμ-myc mice